ALSO NOTED: Tsumura returns rights to hypertension drug; FDA announces Perrigo recall; BioMarin files NDA for Orapred ODT; and

> Tsumura and Dainippon Pharmaceutical have returned the development and marketing rights to the hypertension drug lercanidipine hydrochloride back to Italy's Recordati. Report

> The FDA has announced a voluntary recall of the infant oral meds made by Perrigo. Pain and cough relief medications distributed with a 1.6ML syringe were recalled because the syringe was not properly marked for dispensing small doses of the treatments. Release

> BioMarin Pharmaceutical of Novato, California, has filed an NDA for Orapred ODT, new formulation of prednisolone that is billed as "convenient and easy to administer." Release

> India's Wockhardt has received FDA permission to market a copycat form of GSK's Ceftin in the US. Story

> Princeton, New Jersey-based Pharmacopeia has raised $8.47 million in a private placement of stock. Release

> UCB Japan and Daiichi have reinforced their marketing pact on Zyrtec. Story

And Finally… Researchers say that Vitamin E has simply failed to live up to its promise to prevent illness. Feature

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.